Literature DB >> 15158164

Substance P inhibits potassium and calcium currents in inner ear spiral ganglion neurons.

Wei Sun1, Da-Lian Ding, Ping Wang, Jianhe Sun, Xiaojie Jin, Richard J Salvi.   

Abstract

Substance P (SP), a member of the tachykinin family of neurotransmitters and neuromodulators, has been identified on spiral ganglion neurons (SGNs) in the inner ear; however, its high affinity receptor, neurokinin-1 (NK1), has not been identified and the physiological effects of SP on SGNs are not well understood. To address these issues, immunolabeling, RT-PCR, Western blots and whole-cell patch-clamp recordings were made from SGNs in P0-P5 mouse cochlear organotypic cultures. The NK1 receptor was detected on SGNs by immunocytochemistry, the protein was detected in cochlear tissues by Western blots, and the mRNA for the NK1 receptor was also found in cochlear tissues of postnatal mice (P2) by RT-PCR. Application of SP (1 to 25 microM) significantly increased the latency of SGN action potentials (APs) (mean increase 7.8 +/- 4 ms; 25 microM of SP), prolonged the duration of the action potential and made the resting potential (RP) more positive (mean 9.0 +/- 7 mV) relative to normal values (-54 +/- 6 mV). SP (1 to 25 microM) also suppressed voltage-activated potassium currents (IK+) and calcium currents (ICa2+). Puffing 25 microM of SP onto SGNs suppressed IK+ by 43 +/- 9% (n = 7) and ICa2+ by 40.6 +/- 5.6% (n = 7); both currents recovered when SP was washed out. A SP antagonist blocked the SP-induced suppression of IK+ and ICa2+. These results indicate that SP acting through NK1 receptors can have direct neuromodulatory effects on SGNs. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158164     DOI: 10.1016/j.brainres.2004.03.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Protein-engineered hydrogel encapsulation for 3-D culture of murine cochlea.

Authors:  David T Chang; Renjie Chai; Rebecca DiMarco; Sarah C Heilshorn; Alan G Cheng
Journal:  Otol Neurotol       Date:  2015-03       Impact factor: 2.311

2.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

Review 3.  Emerging pharmacotherapy of tinnitus.

Authors:  Berthold Langguth; Richard Salvi; Ana Belén Elgoyhen
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

Review 4.  Pathophysiology and treatment of tinnitus: an elusive disease.

Authors:  Alp Atik
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-15

Review 5.  Diverse identities and sites of action of cochlear neurotransmitters.

Authors:  Siân R Kitcher; Alia M Pederson; Catherine J C Weisz
Journal:  Hear Res       Date:  2021-05-24       Impact factor: 3.672

6.  The Three-Dimensional Culture System with Matrigel and Neurotrophic Factors Preserves the Structure and Function of Spiral Ganglion Neuron In Vitro.

Authors:  Gaoying Sun; Wenwen Liu; Zhaomin Fan; Daogong Zhang; Yuechen Han; Lei Xu; Jieyu Qi; Shasha Zhang; Bradley T Gao; Xiaohui Bai; Jianfeng Li; Renjie Chai; Haibo Wang
Journal:  Neural Plast       Date:  2016-01-06       Impact factor: 3.599

7.  Chronic Primary Tinnitus: A Management Dilemma.

Authors:  Annanya Soni; Abhishek Dubey
Journal:  Audiol Res       Date:  2020-11-25

8.  Prior Acoustic Trauma Alters Type II Afferent Activity in the Mouse Cochlea.

Authors:  Nathaniel Nowak; Megan Beers Wood; Elisabeth Glowatzki; Paul Albert Fuchs
Journal:  eNeuro       Date:  2021-11-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.